Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Table 1 Patient characteristics

Cohort	Case	Age/gender	Diagnosis	Disease stage	ECOG/PS	Prior treatment	Combined treatment (chemotherapy)	NK cell administration
1	1	57/M	Rectal cancer	Recurrent	1	Surgery, chemotherapy	None	Excluded from trial^a
	2	74/F	Rectal cancer	Recurrent	0	Surgery, chemotherapy	S-1	Excluded from trial^a
	3	61/M	Esophageal cancer	Metastatic	2	Chemotherapy, radiation therapy	None	Complete
	4	62/M	Gastric cancer	Recurrent	2	Surgery, chemotherapy	S-1	Incomplete (2 times)
	5	72/M	Esophageal cancer	Recurrent	0	Surgery, chemotherapy	None	Complete
	6	73/M	Colon cancer	Recurrent	0	Surgery, chemotherapy	None	Complete
	7	66/M	Gastric cancer	Metastatic	0	Chemotherapy	None	Complete
2	8	62/M	Esophageal cancer	Recurrent	0	Surgery, chemotherapy, radiation therapy	None	Complete
	9	65/M	Colon cancer	Metastatic	0	Chemotherapy	S-1	Complete
	10	67/M	Esophageal cancer	Metastatic	2	Chemotherapy, radiation therapy	None	Incomplete (2 times)
	11	69/M	Gastric cancer	Metastatic	0	Chemotherapy	None	Complete
3	12	60/M	Colon cancer	Recurrent	0	Surgery, chemotherapy	None	Complete
	13	78/F	Rectal cancer	Recurrent	0	Surgery, chemotherapy	None	Complete
	14	48/F	Rectal cancer	Recurrent	0	Surgery, chemotherapy, radiation therapy	None	Complete

ECOG Eastern Coorperative Oncology Group, PS performance status
^aTwo patients were excluded from trial because the purity (no. 1) or the number (no. 2) of expanded cells didn’t exceed eligible value